BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
2.000
-0.090 (-4.31%)
At close: Nov 4, 2024, 4:00 PM
2.010
+0.010 (0.50%)
After-hours: Nov 4, 2024, 7:28 PM EST
BioAtla Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
65
Market Cap
96.67M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Assertio Holdings | 132.19M |
FONAR | 102.88M |
Harvard Bioscience | 101.13M |
MDxHealth | 80.74M |
OptiNose | 75.06M |
BCAB News
- 27 days ago - BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy - Seeking Alpha
- 4 weeks ago - BioAtla: Numerous Catalysts Coming In Q4 - Seeking Alpha
- 4 weeks ago - BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting - GlobeNewsWire
- 4 weeks ago - BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress - GlobeNewsWire
- 6 weeks ago - BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody - GlobeNewsWire
- 3 months ago - BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day - GlobeNewsWire
- 5 months ago - BioAtla to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire